Brimo
Generic Name
Brimonidine Tartrate
Manufacturer
Various (e.g., Incepta Pharmaceuticals Ltd. in Bangladesh)
Country
Bangladesh (for local brands), USA (for innovator)
Loading images...
Price Details
Current market pricing information
| Variant | Unit Price | Strip Price |
|---|---|---|
| brimo 02 eye drop | ৳ 80.30 | N/A |
Description
Overview of the medicine
Brimonidine Tartrate ophthalmic solution is a topical alpha-2 adrenergic agonist indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. It works by decreasing aqueous humor production and increasing uveoscleral outflow.
Uses & Indications
Dosage
Adults
One drop in the affected eye(s) three times daily, approximately 8 hours apart.
Elderly
No dosage adjustment needed for elderly patients.
Renal_impairment
Use with caution in patients with severe renal impairment, though systemic absorption is minimal.
How to Take
For ophthalmic use only. Apply one drop into the conjunctival sac of the affected eye(s). Avoid touching the dropper tip to any surface to prevent contamination. If using other eye drops, wait at least 5-10 minutes between applications.
Mechanism of Action
Brimonidine is a highly selective alpha-2 adrenergic agonist. It reduces elevated intraocular pressure by dual mechanisms: decreasing aqueous humor production and increasing uveoscleral outflow. The onset of action occurs within one hour of administration, with the maximum ocular hypotensive effect occurring at two hours post-dosing.
Pharmacokinetics
Onset
Within 1 hour
Excretion
Excreted primarily via the kidneys as metabolites.
Half life
Approximately 2-3 hours systemically, but the ocular effect lasts up to 12 hours.
Absorption
Minimal systemic absorption occurs following topical ocular administration. Peak plasma concentrations are generally low (around 40 pg/mL) and achieved within 1-4 hours.
Metabolism
Primarily hepatic metabolism.
Side Effects
Contraindications
- Hypersensitivity to Brimonidine Tartrate or any component of the formulation.
- Neonates and infants (under 2 years of age) due to potential for serious systemic side effects, including apnea and bradycardia.
Drug Interactions
Tricyclic Antidepressants (TCAs)
Can interfere with the ocular hypotensive effect of Brimonidine. Caution is advised.
Antihypertensives / Cardiac Glycosides
May potentiate blood pressure lowering effects. Use with caution.
CNS Depressants (e.g., alcohol, barbiturates, opiates, sedatives, anesthetics)
May enhance CNS depressant effects. Use with caution.
Storage
Store at room temperature (15-25°C), protected from light. Do not freeze. Keep the bottle tightly closed when not in use.
Overdose
Systemic overdose is unlikely with topical ocular administration. However, in cases of accidental oral ingestion, symptoms may include hypotension, bradycardia, hypothermia, somnolence, and CNS depression. Treatment is supportive and symptomatic, with airway management as needed.
Pregnancy & Lactation
Pregnancy: Category B. Studies in animals have not shown a risk, but there are no adequate and well-controlled studies in pregnant women. Use only if clearly needed. Lactation: It is unknown whether Brimonidine is excreted in human milk. Caution should be exercised when administered to a nursing woman.
Frequently Asked Questions
Common questions about this medicine
Pack Sizes
Shelf Life
24-36 months (unopened), 28 days (after opening)
Availability
Pharmacies, Hospitals, Eye Clinics
Approval Status
Approved by FDA and DGDA
Patent Status
Generic versions available, original patent expired
Clinical Trials
Extensively studied in clinical trials for efficacy and safety in open-angle glaucoma and ocular hypertension. Showed significant IOP reduction compared to placebo and sometimes other antiglaucoma agents. Some trials focused on neuroprotective potential, though not an approved indication.
Lab Monitoring
- Regular intraocular pressure (IOP) measurement.
- Periodic eye examinations to monitor for efficacy and side effects.
Doctor Notes
- Advise patients about potential for drowsiness, especially when initiating therapy.
- Caution should be exercised when co-administering with other CNS depressants.
- Regular monitoring of IOP is crucial.
Patient Guidelines
- Do not wear contact lenses during treatment or remove them before applying the drops and wait at least 15 minutes before reinserting.
- Wash hands thoroughly before and after using the eye drops.
- Avoid contamination of the dropper tip.
- Inform your doctor about all other medications you are using, especially other eye drops.
Missed Dose Advice
If a dose is missed, apply it as soon as possible. If it is almost time for the next dose, skip the missed dose and resume your regular dosing schedule. Do not double the dose.
Driving Precautions
Brimonidine may cause drowsiness or fatigue, and blurred vision. Patients should be warned about engaging in hazardous activities such as driving or operating machinery until they are certain that Brimonidine does not adversely affect their ability to perform such activities.
Lifestyle Advice
- Avoid driving or operating machinery if you experience blurred vision or drowsiness after using the drops.
- Maintain regular follow-up appointments with your ophthalmologist.
Alternative Medicines in Bangladesh
Similar medicines available in the market
Global Brand Names
International brand names for this medicine. Click a brand to search for detailed information.